Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2023 the Company granted inducement awards to purchase up to 121,150 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
About Syndax
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin?KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contact
Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827
Wanbang Digital Energy Co., Ltd, also known for its brand name "StarCharge", a global leader in electronic vehicle (EV) charging solutions and microgrid technology, has signed a Memorandum of Understanding with Schneider Electric (SU.PA), the leader...
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, is proud to report an increase in net sales with 10% to SEK 427.2 million (387.1) and earning per share increased with 27 per cent to SEK 0.38 (0.30)....
Highlights
Reported revenues (GiG Media) at all-time high of ?28.0m (18.4), an increase of 52% (21% organic), with an EBITDA of ?13.5 (8.0)The group, including Platform & Sportsbook achieved all-time high revenues amounting to ?36.2m...
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the...
January?March 2024
Net sales decreased by 2 percent to SEK 6,792m (6,927).Gross profit increased by 2 percent to SEK 2,312m (2,260).EBITDA rose by 11 percent to SEK 768m (692).Adjusted EBITDA1 decreased by 5 percent to SEK 794m (834).The loss after...
4me®, the SaaS-based Service Management software platform for the modern enterprise, announces its 9th annual Connect event, 4me Connect 24, on May 14-16, at Beurs van Berlage in Amsterdam. This year's groundbreaking assembly of service management...
